iPSC Humanized Mouse Models

iPSC humanized mouse models use human immune components derived from induced pluripotent stem cells rather than from a donor blood or cord blood sample. Altogen Labs offers this as a validated platform for preclinical immunology and immuno-oncology studies where an iPSC-derived human immune compartment provides the appropriate experimental system.

The distinguishing characteristic is the source material. Donor-derived platforms depend on a finite sample from a specific individual, and when that sample is exhausted the model cannot be reproduced exactly. An induced pluripotent stem cell line is renewable and genetically defined, which changes what is possible across a program: the same immune genetic background can be used in studies separated by months, and comparisons between studies are not confounded by a change of donor.

To discuss whether an iPSC-derived platform suits a program, request a quote.

Where the platform fits

iPSC humanized models are appropriate where reproducibility across studies matters more than representing inter-individual variation, where a defined and renewable immune source is preferable to a donor-derived one, or where the program will run long enough that donor material would have to be replaced partway through.

They sit alongside rather than replace the donor-derived platforms. Peripheral blood reconstitution remains the fastest route to a T-cell dependent readout. CD34-positive reconstitution and the ATO-supported BLT platform remain the appropriate choices where multilineage human immunity or structured T-cell development is required. Where a study is specifically about variability between individuals, a donor-derived platform is the correct choice and an iPSC-derived one would answer the wrong question.

Study configuration

Studies are configured according to the immune lineage of interest, the therapeutic mechanism, host requirements, intended study duration, and the downstream endpoints required. Model-specific reconstitution and eligibility criteria are established in the study protocol and verified before animals enter treatment, as with any humanized platform. Tumor configuration follows the same options available across the humanized service line, including subcutaneous, orthotopic, and disseminated models.

Applications

The platform supports immuno-oncology and translational studies involving immune-modulating agents, engineered cell approaches, tumor-immune interactions, and other questions for which an iPSC-derived human immune component is appropriate. It is also applicable where the immune source itself is the therapeutic product under investigation, since iPSC-derived effector cells are an active area of cell therapy development.

Endpoints

Applicable endpoints include tumor response and survival, flow cytometric immune profiling, cytokine analysis, immunohistochemistry, tissue collection, and molecular or protein analysis, selected according to the platform configuration and study objective.

Applied examples

Cross-study comparability. A candidate agent is evaluated in an initial study and again several months later against a modified schedule, using the same iPSC-derived immune background in both, so that the schedules can be compared without a change of donor confounding the result.

Defined genetic background. A mechanism dependent on a specific immune genotype is studied in a line carrying that genotype, rather than searching for a donor sample that happens to have it.

Engineered effector cells. An iPSC-derived effector cell product is evaluated for antitumor activity and persistence in a tumor-bearing host, with immune profiling and tumor endpoints measured in the same animals.

Protocol definition and reporting

Because platform configuration varies by program to a greater degree than with donor-derived systems, the study protocol defines the immune component, reconstitution and eligibility criteria, treatment window, endpoint panel, and analysis plan explicitly for each project rather than inheriting them from a standard template. All procedures are conducted under active IACUC protocols. GLP standards are applied where a study is formally designated as GLP.

Send mechanism, required immune lineages, and study duration, or request a quote.